Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Innate Pharma announces its financial calendar for 2013 as well as its participation to upcoming investor conferences
Phase I clinical trial of IPH2102/BMS-986015 in combination with ipilimumab announced
First patient treated in the EffiKIR trial
Update on clinical trials with IPH2101 in Multiple Myeloma
Innate Pharma announces revenue for the first nine months of 2012 and updates on its cash position
Innate Pharma to meet its retail investors at Actionaria on November 23 & 24
First clinical trial with IPH2102/BMS-986015 sponsored by Bristol-Myers Squibb announced
Results of IPH2101 Phase I trial in AML published in BLOOD
Financial results for the first half of 2012
